FARALLON CAPITAL MANAGEMENT LLC - CRINETICS PHARMACEUTICALS IN ownership

CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
FARALLON CAPITAL MANAGEMENT LLC ownership history of CRINETICS PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$10,763,025
+276.3%
361,904
+279.5%
0.05%
+157.1%
Q4 2018$2,860,000
-29.6%
95,365
-32.8%
0.02%
-12.5%
Q3 2018$4,063,000141,8150.02%
Other shareholders
CRINETICS PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Saturn V Capital Management LP 623,819$11,336,5019.41%
Finepoint Capital LP 822,745$15,0564.87%
Bain Capital Life Sciences Investors, LLC 2,305,558$42,1924.72%
Opaleye Management Inc. 732,000$13,395,6004.66%
5AM Venture Management, LLC 862,286$15,779,8344.24%
SPHERA FUNDS MANAGEMENT LTD. 671,644$12,291,0852.64%
First Light Asset Management, LLC 1,329,313$24,326,4282.26%
BRAIDWELL LP 3,469,674$63,495,0342.13%
BVF INC/IL 2,736,613$50,080,0182.11%
Perceptive Advisors 4,039,276$73,918,7512.08%
View complete list of CRINETICS PHARMACEUTICALS IN shareholders